The development of oxytocic drugs in the management of postpartum haemorrhage Thomas F Baskett Throughout history obstetric haemorrhage has been a major cause of maternal mortality in both developed and developing countries.1' 2The oldest work in obstetrics and gynaecology, published toward the end ofthe first century AD, is attributed to Soranus of Ephesus, who brought together the knowledge of obstetrics, gynaecology and paediatrics of that era.3 Soranus gives no account of oxytocic medications but does give some sensible advice on the general management of hyopvolaemic shock associated with postpartum haemorrhage, advising that the woman should 'lie down in a relatively small, dark and moderately cool room upon a hard bed ... raised a little at the foot'. He also described what could be regarded as the forerunner of the Medical Antishock Trousers (MAST): 'and the extremities should be gripped tightly and bandaged, for the compression resulting from this squeezing is transmitted all the way to the affected part'.'
Uterine atony accounts for 80-85% of all cases of primary postpartum haemorrhage (PPH). Once the placenta separates from the uterine wall in the third stage of labour, it leaves a very vascular placental bed with torn blood vessels. The uterine musculature, through which the blood vessels that supply the placental bed pass, is arranged in an interlocking criss-cross fashion, such that contraction of these muscle fibres effectively constricts the blood vessels. 4 The first effective oxytocic drug was ergot, derived from the fungus Claviceps purpurea that grew on the ears of cereal grains, particularly rye. The disease ergotism was caused by eating rye bread contaminated with the fungus ergot. Epidemics of ergotism have occurred for more than 1000 years and were caused by wet seasons leading to damp cereal crops which favoured growth of the fungus. These epidemics tended to occur in areas of France, Russia and Southern Germany where the cereal rye was grown extensively. The usual manifestation was gangrene of the peripheries associated with progressive vasospasm. The more rare type of ergotism mainly involved the central nervous system and was known as the convulsive variety. During epidemics of ergotism it was observed that pregnant women would miscarry and midwives therefore deduced that ergot caused uterine contractions and began using it for prolonged labour with ineffective uterine contractions8' 9 It was administered by grinding up the grains of the fungus and administering it in powder form. It came to be called pulvis ad partum (the powder of birth). It was probably used first and most extensively by midwives in Germany, and the first written reference is by Adam Lonicer in his Krauterbuch or Book of Herbs in 1582. 10 In 1787 Paulitsky noted the increasing use of ergot in labour, claiming: ... all are reassured that it makes labour quicker and more powerful than any other remedies'. 1 The use of ergot in obstetrics increased following the 1808 publication of a letter by John Stearns in the Medical Respository ofNew York. 12 Working in rural New York, Stearns apparently learned of ergot from 'an ignorant Scottish midwife'. In his letter, written to a colleague in 1807, he outlined the advantages of ergot to 'expedite lingering parturition'. He observed that the pains stimulated by ergot were 'peculiarly forcing'. He also noted that the response to ergot could be very rapid, claiming "since I have adopted the use of this powder I have seldom found a case that detained me more than three hours".'2 Unfortunately, the response to ergot was unpredictable and as a result tetanic uterine contractions led to fetal asphyxia, stillbirth and uterine rupture. Stearns himself was later to emphasize the 'necessity of extreme caution'.'3 The misuse of ergot and its complications were summarized by David Hosack who felt the name should be changed to pulvis ad mortem. ' which work Du Vigneaud later received the Nobel Prize. In 1953 he achieved synthesis of oxytocin.33 Thus, by the 1 950s both oxytocin and ergometrine were in widespread use both for the prevention and the management ofpostpartum haemorrhage. By the 1980s several randomised controlled trials and subsequent meta analysis confirmed the effectiveness of active management of the third stage oflabour in reducing blood loss, postpartum haemorrhage, the need for therapeutic doses of oxytocic drugs and the need for blood transfusion.29'34 Active management of the third stage may also reduce the risk of acute uterine inversion.35 Both oxytocin and ergometrine are effective but the side effect profile of ergometrine is greater so that oxytocin has become the drug of first choice.34 DEVELOPMENT (Table) . Oxytocin and ergometrine, or a combination thereof, remain the standard oxytocics for the prevention and treatment of PPH. The more expensive 15-methyl PGF2a is a valuable alternative in cases unresponsive to oxytocin and/or ergometrine. Misoprostol does not require injection for its administration and is the cheapest, most stable, and easily stored of all oxytocic drugs. As such it has the most potential for widespread use and benefit in the developing world, where 99% of maternal deaths due to PPH occur. However, the efficacy, dose, and route of administration (oral, sublingual, rectal) have yet to be delineated.5' 
